Healthcare
China's Ribo Life Science raises $40m as part of Series E
Chinese drug developer Suzhou Ribo Life Science has raised USD 40m in the first tranche of a Series E from existing investors Panlin Capital and Trinity Innovation Fund. Several undisclosed new investors also took part.
ABC Impact backs China autism therapy business
ABC Impact, a Singapore-based impact investor established by Temasek Trust, the philanthropic arm of Temasek Holdings, has led a USD 42m Series D for Da Mi & Xiao Mi (DMXM), a Chinese rehabilitation platform for children with autism spectrum disorder...
Sylvan buys Singapore orthopaedics business
Singapore-based private equity firm Sylvan Group has taken a controlling position in Singapore Orthopaedic Specialists (SOS) as a bolt-on of recently acquired Artemis Health Ventures.
India's ASG Eye Hospitals gets $188m from Kedaara, GA
Indian optometry chain ASG Eye Hospital has raised a INR 15bn (USD 188m) round led by Kedaara Capital and General Atlantic, setting up an exit for Investcorp.
Deal focus: Navis penetrates Thai hospital segment
Navis Capital Partners’ acquisition of NP Medical extends its coverage of the Southeast Asia hospital space to a third geography while tapping into a general trend towards specialty providers
Navis buys majority stake in Thai hospital operator
Navis Capital Partners has invested an undisclosed sum for a majority position in NP Medical, owner and operator of S-Spine, a spine and nerve specialty hospital in Thailand.
RRJ to invest $251m in Singapore's Fullerton Health
RRJ Capital is poised to invest SGD 350m (USD 251m) in Singapore-based integrated healthcare platform Fullerton Healthcare Corporation after the target company settled a dispute with two of its co-founders.
Deal focus: SJL fills Korea’s cross-regional gap
Steve Lim launched SJL Partners to help Korean corporates pursue M&A in the US and Europe, having seen global GPs pass on such opportunities. Meridian Bioscience is the latest addition to the portfolio
Philippines venture builder, Ayala engineer health-tech merger
917Ventures, a corporate venture builder controlled by Philippines-based telecom operator Globe Group, has merged its KonsultaMD telehealth platform with assets held by Ayala Corporation to create a one-stop health super app.
2Q analysis: Substituting China?
India and Southeast Asia come to the fore as China demonstrates weakness in both growth-stage investment and fundraising; exits continue to struggle amid reluctance from strategic buyers
Fund focus: Qiming picks its moment
China’s Qiming Venture Partners more than doubled its fund size from the previous vintage, having launched the vehicle prior to the recent chaos and leveraged LP demand for the familiar
China medical big data player Aden secures $30m
Aden Technology, a China-based medical big data company specialising in insurance, has raised an extended Series B round of CNY 200m (USD 30m) led by Haier Capital with participation from Xingtuo Capital.
Qiming raises $3.2b across dollar, renminbi funds
China-focused VC firm Qiming Venture Partners has closed its eighth US dollar-denominated fund at the hard cap of USD 2.5bn – more than twice the size of the previous vintage – and raised CNY 4.7bn (USD 701m) for its latest renminbi vehicle.
Korean GP backs $1.5b buyout of US-listed Meridian Bioscience
SJL Partners, a Korea-based private equity firm that specialises in cross-border transactions, has teamed up with domestic in vitro diagnostics business SD Biosensor to acquire US-listed peer Meridian Bioscience for USD 1.53bn.
Australian start-up wins backing for spider venom drug
Infensa Bioscience, a newly established Brisbane-based drug developer, has raised AUD 23m (USD 15.6m) in funding to support the licensing of a nascent treatment that uses spider venom to mitigate heart attacks and strokes.
Legend leads $150m Series E for China CRO ClinChoice
US and China-based clinical contract research organization (CRO) company ClinChoice has raised a USD 150m Series E round led by Legend Capital.
Sequoia raises $8.8b for China funds
Sequoia Capital has hit the hard cap on each of the four funds in its latest China vintage, accumulating USD 8.8bn for deployment in seed through late-growth rounds.
Arpwood leads acquisition of India's Sterling Hospitals
Indian private equity firm Arpwood Capital has led the acquisition of Sterling Addlife India, operator of the Sterling Hospitals chain, for an undisclosed sum.
China biotech: End of the boom
PE investment in China biotech has collapsed amid failed IPO processes and disputed valuations. Pockets of activity remain, though questions around commercialisation have yet to be answered
China RNA vaccine developer raises $42m
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
AstraZeneca-CICC fund backs China gene sequencer
Axbio, a China-based provider of gene sequencing and diagnostic systems, has raised nearly USD 100m in Series B funding led by AstraZeneca-CICC Healthcare Industrial Fund and Yunfeng Capital.
China bio-manufacturing start-up Mojia raises $80m
Temasek Holdings has led a USD 80m Series B round for Shanghai-based bio-manufacturing start-up Mojia Biotech.
5Y leads $74m round for China AI drug developer
Beijing-based HeliXon, an artificial intelligence-enabled developer of protein-based drugs, has raised CNY 500m (USD 75m) in Series A funding led by 5Y Capital. Other investors include Gaorong Capital and Neumann Capital.
China life sciences research business gets $300m Series C
MegaRobo Technologies, a China-based provider of artificial intelligence (AI) and robotics-enabled research services to the life sciences industry, has raised USD 300m in Series C funding.